Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA Facility Fees Should Be Waived Until First ANDA Approved, Petition Argues

Executive Summary

Bangladesh-based Square Pharmaceuticals says the fees are burdensome for first-time filers, given long approval times, but the firm’s citizen petition strategy may further delay approval of its ANDA.

Advertisement

Related Content

FDA Says It’s The Law, Denies Petition Requesting GDUFA Fee Payment Changes
GDUFA Grace Period For Facility Fees Appears To Be Over
FDA Generics Director’s Departure Shows Why Chemistry Matters
Generic User Fee Waivers Dropped In Latest House Draft Bill
Generic User Fee Waivers Created In Draft House Bill, Breaking FDA-Industry Agreement
FDA, Industry Reach Agreement On Major Portions Of Generic User Fee Program

Topics

Advertisement
UsernamePublicRestriction

Register

PS055192

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel